FMS vs. NTRA, HIMS, RDNT, OPCH, GH, SHC, VCYT, BTSG, LFST, and SGRY
Should you be buying Fresenius Medical Care stock or one of its competitors? The main competitors of Fresenius Medical Care include Natera (NTRA), Hims & Hers Health (HIMS), RadNet (RDNT), Option Care Health (OPCH), Guardant Health (GH), Sotera Health (SHC), Veracyte (VCYT), BrightSpring Health Services (BTSG), LifeStance Health Group (LFST), and Surgery Partners (SGRY). These companies are all part of the "healthcare" industry.
Fresenius Medical Care vs.
Fresenius Medical Care (NYSE:FMS) and Natera (NASDAQ:NTRA) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Natera received 60 more outperform votes than Fresenius Medical Care when rated by MarketBeat users. Likewise, 68.96% of users gave Natera an outperform vote while only 54.66% of users gave Fresenius Medical Care an outperform vote.
Fresenius Medical Care has a net margin of 3.43% compared to Natera's net margin of -14.01%. Fresenius Medical Care's return on equity of 6.04% beat Natera's return on equity.
In the previous week, Natera had 14 more articles in the media than Fresenius Medical Care. MarketBeat recorded 14 mentions for Natera and 0 mentions for Fresenius Medical Care. Natera's average media sentiment score of 0.56 beat Fresenius Medical Care's score of 0.00 indicating that Natera is being referred to more favorably in the news media.
Fresenius Medical Care has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Natera has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500.
Fresenius Medical Care has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Fresenius Medical Care, indicating that it is currently the more affordable of the two stocks.
8.4% of Fresenius Medical Care shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 7.6% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Fresenius Medical Care presently has a consensus target price of $25.30, indicating a potential upside of 9.57%. Natera has a consensus target price of $160.63, indicating a potential upside of 1.43%. Given Fresenius Medical Care's higher possible upside, research analysts clearly believe Fresenius Medical Care is more favorable than Natera.
Summary
Natera beats Fresenius Medical Care on 10 of the 18 factors compared between the two stocks.
Get Fresenius Medical Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for FMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fresenius Medical Care Competitors List
Related Companies and Tools
This page (NYSE:FMS) was last updated on 1/21/2025 by MarketBeat.com Staff
